2 results
Approved WMOPending
- The primary objective is to determine the dose limiting toxicity and the maximum tolerated dose and recommended dose of the combination of temsirolimus weekly and nelfinavir orally BID to patients with advanced solid tumors.- Secondary objective…
Approved WMORecruiting
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.